Furthermore, a negative correlation between the expression of IRF8 and the abundance of the immature CD33+HLA-DR− MDSC subset in breast cancer patients substantiated the important role of IRF8 as a negative regulator of PMN-MDSC levels originally observed in mouse tumor models. Here, IRF8 is linked to breast cancer.